481 related articles for article (PubMed ID: 17630360)
21. E3710, a new proton pump inhibitor, with a long-lasting inhibitory effect on gastric acid secretion.
Kodama K; Fujisaki H; Kubota A; Kato H; Hirota K; Kuramochi H; Murota M; Tabata Y; Ueda M; Harada H; Kawahara T; Shinoda M; Watanabe N; Iida D; Terauchi H; Yasui S; Miyazawa S; Nagakawa J
J Pharmacol Exp Ther; 2010 Aug; 334(2):395-401. PubMed ID: 20484556
[TBL] [Abstract][Full Text] [Related]
22. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
[TBL] [Abstract][Full Text] [Related]
23. The mechanism of action of omeprazole--a survey of its inhibitory actions in vitro.
Wallmark B; Lorentzon P; Larsson H
Scand J Gastroenterol Suppl; 1985; 108():37-51. PubMed ID: 2988109
[TBL] [Abstract][Full Text] [Related]
24. Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Brehm C; Buhr W; Palmer AM; Volz J; Simon WA
Bioorg Med Chem; 2008 Jan; 16(1):536-41. PubMed ID: 17964794
[TBL] [Abstract][Full Text] [Related]
25. Antisecretory actions of Baccharis trimera (Less.) DC aqueous extract and isolated compounds: analysis of underlying mechanisms.
Biondo TM; Tanae MM; Coletta ED; Lima-Landman MT; Lapa AJ; Souccar C
J Ethnopharmacol; 2011 Jun; 136(2):368-73. PubMed ID: 21575703
[TBL] [Abstract][Full Text] [Related]
26. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo.
Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG
J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865
[TBL] [Abstract][Full Text] [Related]
27. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
[TBL] [Abstract][Full Text] [Related]
28. Mechanism of gastric antisecretory effects of nolinium bromide.
Nandi J; Wright MV; Ray TK
Gastroenterology; 1983 Oct; 85(4):938-45. PubMed ID: 6309605
[TBL] [Abstract][Full Text] [Related]
29. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective.
Orlando RC
Am J Gastroenterol; 1996 Sep; 91(9):1692-6. PubMed ID: 8792683
[TBL] [Abstract][Full Text] [Related]
30. Novel indanyl-substituted imidazo[1,2-a]pyridines as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Buhr W; Brehm C; Palmer AM; Feth MP; Senn-Bilfinger J; Simon WA
Bioorg Med Chem Lett; 2007 Oct; 17(19):5374-8. PubMed ID: 17723299
[TBL] [Abstract][Full Text] [Related]
31. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration.
Robert A; Schultz JR; Nezamis JE; Lancaster C
Gastroenterology; 1976 Mar; 70(3):359-70. PubMed ID: 174967
[TBL] [Abstract][Full Text] [Related]
32. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
Shin JM; Cho YM; Sachs G
J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
[TBL] [Abstract][Full Text] [Related]
33. 2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6-tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors.
Yamada M; Yura T; Morimoto M; Harada T; Yamada K; Honma Y; Kinoshita M; Sugiura M
J Med Chem; 1996 Jan; 39(2):596-604. PubMed ID: 8558532
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of gastric H+, K+-ATPase by 3-amino-5-methyl-2-(2-methyl-3-thienyl)imidazo[1,2-a]thieno[3,2-c]pyrid ine, SPI-447.
Ushiro T; Tsukimi Y; Tanaka H
Jpn J Pharmacol; 1997 Nov; 75(3):303-6. PubMed ID: 9434264
[TBL] [Abstract][Full Text] [Related]
35. Developments in the inhibition of gastric acid secretion.
Mössner J; Caca K
Eur J Clin Invest; 2005 Aug; 35(8):469-75. PubMed ID: 16101666
[TBL] [Abstract][Full Text] [Related]
36. Novel 1H-pyrrolo[2,3-c]pyridines as acid pump antagonists (APAs).
Yoon YA; Kim DH; Lee BM; Kim TK; Cha MH; Sim JY; Kim JG
Bioorg Med Chem Lett; 2010 Sep; 20(17):5237-40. PubMed ID: 20656486
[TBL] [Abstract][Full Text] [Related]
37. Antiulcerogenic and ulcer healing effects of Solanum nigrum (L.) on experimental ulcer models: possible mechanism for the inhibition of acid formation.
Jainu M; Devi CS
J Ethnopharmacol; 2006 Mar; 104(1-2):156-63. PubMed ID: 16202548
[TBL] [Abstract][Full Text] [Related]
38. Effect of the novel histamine H2-antagonist 5,6-dimethyl-2-[4-[3-(1- piperidinomethyl)phenoxy]-(z)-2-butenylamino]-4(1H)-pyrimidine dihydrochloride on histamine-induced gastric acid secretion in Heidenhain pouch dogs.
Uchida M; Ohba S; Ikarashi Y; Misaki N; Kawano O
Arzneimittelforschung; 1993 Aug; 43(8):873-6. PubMed ID: 8105784
[TBL] [Abstract][Full Text] [Related]
39. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
Yamaguchi T; Aihara K; Yamada S; Narita S; Kogi K
Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
[TBL] [Abstract][Full Text] [Related]
40. Gastric antisecretory and antiulcer/cytoprotective effects of 2-cyano-3-(ethylthio-3-methylthio)-2-propenoic acid methyl ester.
Borella LE; DiJoseph JF
Arzneimittelforschung; 1989 May; 39(5):598-601. PubMed ID: 2547390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
